Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Patient Considerations for New Systemic Treatments for Prurigo Nodularis : Episode 8

Opinion

Video

December 19, 2024

New Systemic Treatment Options for Prurigo Nodularis

Author(s):

TJ Chao, MPAS, PA-C, discusses how the recently approved systemic biologic treatments for prurigo nodularis (PN), dupilumab and nemolizumab, differ in their mechanisms of action, efficacy, safety profiles, and how they compare to other treatment options for PN.

EP: 1.Prurigo Nodularis Burden of Disease

EP: 2.Challenges in Diagnosing Prurigo Nodularis and Distinguishing From Other Pruritic Conditions

EP: 3.New Systemic Treatments for Prurigo Nodularis

EP: 4.Talking to Patients About Itch Management

EP: 5.Provider and Patient Considerations for Prurigo Nodularis Treatment

EP: 6.The Burden of Prurigo Nodularis

EP: 7.Considerations for Setting Treatment Goals in Prurigo Nodularis

Now Viewing

EP: 8.New Systemic Treatment Options for Prurigo Nodularis

Video content above is prompted by the following:

There are two 2 systemic biologic treatments that have been recently approved for prurigo nodularis within the past few years. Can you describe these two 2 agents, including mechanisms of action, efficacy and safety, and what differentiates them from each other and from other PN treatment options?